MediciNova FY2026 Earnings Forecast Boosted by HC Wainwright

MediciNova, Inc. (NASDAQ:MNOV – Free Report) – Stock analysts at HC Wainwright raised their FY2026 earnings estimates for MediciNova in a report released on Monday, November 16th. HC Wainwright analyst L. Egana-Gorrono now forecasts that the biopharmaceutical company will earn ($0.21) per share for the year, up from their prior estimate of ($0.28). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MediciNova’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for MediciNova’s Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.35) EPS, FY2028 earnings at $0.39 EPS, FY2029 earnings at $2.02 EPS and FY2030 earnings at $3.15 EPS.

Other research analysts have also issued reports about the stock. Roth Capital initiated coverage on shares of MediciNova in a research note on Thursday, September 17th. They issued a “buy” rating and a $6.00 price target on the stock. Weiss Ratings upgraded MediciNova from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MediciNova presently has an average rating of “Moderate Buy” and an average target price of $7.75.

View Our Latest Analysis on MNOV

MediciNova Price Performance

MNOV stock opened at $1.27 on Wednesday. MediciNova has a 52 week low of $1.22 and a 52 week high of $3.90. The firm has a 50-day simple moving average of $1.75 and a 200-day simple moving average of $1.49.

MediciNova (NASDAQ:MNOV – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). MediciNova had a negative net margin of 1,126.60% and a negative return on equity of 26.47%. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.05 million.

Insider Activity at MediciNova

In related news, major shareholder 3D Investment Partners Pte. Lt sold 640,000 shares of the stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $2.70, for a total value of $1,728,000.00. Following the completion of the sale, the insider owned 4,862,047 shares of the company’s stock, valued at approximately $13,127,526.90. This trade represents a 11.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 14.00% of the company’s stock.

Institutional Trading of MediciNova

Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. acquired a new stake in shares of MediciNova in the 3rd quarter worth $1,032,000. Bank of New York Mellon Corp purchased a new position in shares of MediciNova during the 2nd quarter worth $103,000. Empowered Funds LLC purchased a new position in shares of MediciNova during the 3rd quarter worth $83,000. Finally, Jump Financial LLC acquired a new position in shares of MediciNova during the 3rd quarter valued at about $30,000. 9.90% of the stock is currently owned by hedge funds and other institutional investors.

About MediciNova

(Get Free Report)

MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders.

Recommended Stories

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.